Cooperative Agreement R01CA189163

This Cooperative Agreement award from the National Cancer Institute (NCI), under the Cancer Detection and Diagnosis Research program (CFDA 93.394), aims to analytically and clinically validate an Epic 900K v2 array-based methylation assay to predict recurrence in stage II melanoma patients. The $310,185 award to New York University School of Medicine will establish the technical sensitivity and reproducibility of the assay, examine the potential interfering effect of melanocytic nevi, and...

The National Cancer Institute (NCI) awarded a Project Grant (CFDA 93.395 - Cancer Treatment Research) in the amount of $999,960.00 to Linnaeus Therapeutics Inc. to support the development of LNS8801, a novel small molecule therapeutic, for the treatment of cutaneous melanoma patients who cannot tolerate immunotherapy. The funding will enable a proof-of-concept study of LNS8801 in melanoma patients with prior immune-related adverse events (IRAEs). Preclinical studies have demonstrated that...

This federal Project Grant award, provided by the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395), supports a 5-year, $706,669 multi-site clinical trial to evaluate the effects of photobiomodulation therapy (PBMT) on chronic lymphedema in head and neck cancer survivors. The study aims to assess the impact of PBMT on the severity of external and internal lymphedema, symptom burden, functional impairments, and quality of life. The project will enroll 150...

The National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) awarded a $667,553 Project Grant to Northwestern University to conduct research on improving mucosal melanoma therapy by harnessing the immunogenicity of the R3LCMV virus. The research project has two key aims: Determine whether neoadjuvant (pre-surgical) administration of R3LCMV improves disease-free survival in dogs with naturally occurring mucosal melanoma through a placebo-controlled veterinary trial. Utilize R3LCMV to...

This Cooperative Agreement award from the National Cancer Institute, a division of the Department of Health and Human Services, provides $380,509 under the Cancer Biology Research program to The Trustees of Columbia University in New York. The award supports research to elucidate the molecular drivers of melanoma liver metastasis and associated resistance to immunotherapies. Specifically, the researchers will characterize a novel preclinical mouse model that recapitulates genomic and...

The National Cancer Institute (NCI) awarded a $238,824 Project Grant under the Cancer Research Manpower (CFDA 93.398) federal grant program to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), to conduct research aimed at optimizing lung cancer treatment decisions and improving quality-adjusted life years. The key products and services to be delivered under this 18-month grant include: 1) Leveraging an ongoing cohort study of ~2,200 patients with stage...

This federal Project Grant award from the National Cancer Institute (CFDA 93.394 Cancer Detection and Diagnosis Research) provides $203,610 to the University of Texas at Austin to develop and validate a "laser microbiopsy" technique for minimally-invasive sampling of melanoma tumors. The key products and services to be delivered under this 3-year award (8/8/2024 - 7/31/2027) include: Refining and characterizing the performance of the laser microbiopsy hardware to harvest micro-sized...

This federal Project Grant award from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research (CFDA 93.393) program provides $700,611 to the Sloan-Kettering Institute for Cancer Research to conduct a practical randomized controlled trial of artificial intelligence (AI) for improving melanoma diagnosis. The key objectives are to: 1) assess clinician perceptions and barriers to adopting AI technology, and develop a mitigation framework to overcome these barriers; and...

The National Cancer Institute (NCI) awarded a $657,844 Project Grant under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to The Medical College of Wisconsin, Inc. (MCW) to examine the efficacy of a 16-week lifestyle intervention on physical function and patient-reported outcomes among 184 individuals with stable multiple myeloma. The project, titled "Moving Forward with Multiple Myeloma," will also explore associations between lifestyle behaviors and prognostic...

This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) for $1,419,108 aims to advance the understanding of how a novel neoadjuvant therapy, which combines the antibody pepinemab (that blocks Semaphorin 4D signaling) with immune checkpoint blockade (nivolumab and/or ipilimumab), impacts the immune system in patients with refractory melanoma. The key research objectives are to: 1) Gain insight into how blocking Semaphorin 4D impacts dendritic cells...